Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Neflamapimod. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 known ✓ | Q16539 | 20/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 17/20 | 1.00 |
| ▸ | MAPK12 | P53778 | 17/20 | 1.00 |
| ▸ | MAPK11 | Q15759 | 17/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | FYN | P06241 | 1/20 | 1.00 |
| ▸ | CSF1R | P07333 | 1/20 | 1.00 |
| ▸ | YES1 | P07947 | 1/20 | 1.00 |
| ▸ | LYN | P07948 | 1/20 | 1.00 |
| ▸ | HCK | P08631 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ROS1 | P08922 | 1/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 1/20 | 1.00 |
| ▸ | FGR | P09769 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | SRC | P12931 | 1/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | EPHA1 | P21709 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Neflamapimod SCHEMBL29396525 | 1.00 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11ABL1 | |
| SCHEMBL19892655 | 0.93 | MAPK14 (0.87) | MAPK14MAPK13MAPK12MAPK11ABL1 | |
| SCHEMBL12139599 | 0.93 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11ABL1 | |
| SCHEMBL14209102 | 0.90 | MAPK14 (0.81) | MAPK14MAPK13MAPK12MAPK11ABL1 | |
| SCHEMBL12139590 | 0.90 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11ABL1 | |
| SCHEMBL20885633 | 0.90 | MAPK14 (0.83) | MAPK14MAPK13MAPK12MAPK11ABL1 | |
| SCHEMBL5635285 | 0.88 | MAPK14 (0.79) | MAPK14MAPK13MAPK12MAPK11ABL1 | |
| SCHEMBL12139595 | 0.86 | MAPK14 (0.77) | MAPK14MAPK13MAPK12MAPK11ABL1 | |
| SCHEMBL12139569 | 0.85 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11ABL1 | |
| SCHEMBL12139555 | 0.85 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1697 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144798-A1 | Disruption of Vascular Smooth Muscle Relaxation by Carfilzomib May be the Primary Reason for CFZ-Induced Vascular Dysfunction | AMGEN INC. (US) | 2026-05-28 | — | — | US | claimed |
| WO-2026087695-A1 | TREATMENT FOR METABOLIC DISORDER | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| WO-2026087680-A1 | TREATMENT FOR CARDIOVASCULAR DISEASE | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| US-20260109951-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | FATE THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | claimed |
| EP-4720261-A1 | NOVEL CULTURE CONDITIONS FOR CLONAL EXPANSION OF NEPHRON PROGENITOR CELLS, GENERATION OF NEPHRON ORGANOIDS, AND RAPID AND SCALABLE MODELING OF POLYCYSTIC KIDNEY DISEASE | University of Southern California (US) | 2026-04-08 | — | — | EP | claimed |
| EP-3445369-B1 | VX-745 FOR USE IN THE TREATMENT OF DEMENTIA | EIP PHARMA LLC (US) | 2026-03-25 | — | — | EP | claimed |
| EP-3996712-B1 | P38ALPHA MAPK INHIBITORS FOR USE IN THE TREATMENT OF DEMENTIA WITH LEWY BODIES | EIP PHARMA INC (US) | 2026-03-18 | — | — | EP | claimed |
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| EP-4704832-A2 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | Biohaven Therapeutics Ltd. (VG) | 2026-03-11 | — | — | EP | claimed |
| US-20260022117-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | ARVINAS OPERATIONS INC (US) | 2026-01-22 | — | — | US | claimed |
| US-20160331736-A1 | DRUG FOR TREATING CORNEAL ENDOTHELIUM BY PROMOTING CELL PROLIFERATION OR INHIBITING CELL DAMAGE | THE DOSHISHA (JP) | 2016-11-17 | — | — | US | claimed |
| EP-3069732-A1 | DRUG FOR TREATING CORNEAL ENDOTHELIUM BY PROMOTING CELL PROLIFERATION OR INHIBITING CELL DAMAGE | The Doshisha (JP) | 2016-09-21 | — | — | EP | claimed |
| US-20150284683-A1 | METHOD, COMBINATION AND/OR COMPOSITION FOR INDUCING CARDIOMYOCYTE DIFFERENTATION | SINGAPORE HEALTH SERVICES PTE LTD (SG) | 2015-10-08 | — | — | US | claimed |
| EP-2882848-A1 | METHOD, COMBINATION AND/OR COMPOSITION FOR INDUCING CARDIOMYOCYTE DIFFERENTATION | Singapore Health Services Pte Ltd (SG) | 2015-06-17 | — | — | EP | claimed |
| US-20140314725-A1 | METHOD FOR PREPARING MESENCHYMAL STEM CELL-LIKE CELLS AND CARDIOMYOCYTE-LIKE CELLS | SINGAPORE HEALTH SERVICES PTE LTD (SG) | 2014-10-23 | — | — | US | claimed |
| WO-2014122298-A1 | INTERLEUKIN-4 INHIBITORS FOR THE TREAMTENT OF NEUTROPENIA | Universität Zürich (CH) | 2014-08-14 | — | — | WO | claimed |
| EP-2707369-A1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | Eip Pharma, LLC (US) | 2014-03-19 | — | — | EP | claimed |
| WO-2014025315-A1 | METHOD, COMBINATION AND/OR COMPOSITION FOR INDUCING CARDIOMYOCYTE DIFFERENTATION | SINGAPORE HEALTH SERVICES PTE LTD (SG) | 2014-02-13 | — | — | WO | claimed |
| WO-2013055297-A1 | METHOD FOR PREPARING MESENCHYMAL STEM CELL-LIKE CELLS AND CARDIOMYOCYTE-LIKE CELLS | SINGAPORE HEALTH SERVICES PTE LTD (SG) | 2013-04-18 | — | — | WO | claimed |
| WO-2012154814-A1 | COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE | EIP PHARMA, LLC (US) | 2012-11-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022117-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | VHL, ADRM1, MDM2 | MAPK14 3953/4885MAPK13 3324/4885MAPK12 3579/4885 |
| US-20260144798-A1 | Disruption of Vascular Smooth Muscle Relaxation by Carfilzomib May be the Primary Reason for CFZ-Induced Vascular Dysfunction | PDE5A, PRKG2, MAPKAPK5 | MAPK14 19/4885MAPK13 15/4885MAPK12 47/4885 |
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | MDM2, UBR4, UBE3A | MAPK14 2142/4885MAPK13 1388/4885MAPK12 3181/4885 |
| US-20260109951-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | PBK, CD4, CD22 | MAPK14 1645/4885MAPK13 902/4885MAPK12 670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.